Bloomberg Law  |  August 31, 2023

The grouping of six insulin products together prompted additional questions on the Biden administration’s implementation procedures, making additional litigation likely from Novo Nordisk and other manufacturers who have not yet entered the fray, said Zachary Baron, an associate director of the Health Policy and the Law Initiative at Georgetown’s O’Neill Institute.

Read more here.